These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36636055)

  • 41. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Mao C; Yang ZY; Hu XF; Chen Q; Tang JL
    Ann Oncol; 2012 Jun; 23(6):1518-25. PubMed ID: 22039088
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial.
    von Einem JC; Heinemann V; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Decker T; Klein S; Held S; Jung A; Kirchner T; Haas M; Holch J; Michl M; Aubele P; Boeck S; Schulz C; Giessen C; Stintzing S; Modest DP
    J Cancer Res Clin Oncol; 2014 Sep; 140(9):1607-14. PubMed ID: 24816724
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Long-Term and Large-Scale Real-World Study in Taiwan: Efficacy of Target Therapy in Stage IV Colorectal Cancer.
    Huang SC; Lin CC; Teng HW; Lin HH; Chang SC; Lan YT; Wang HS; Yang SH; Chen WS; Jiang JK
    Front Oncol; 2022; 12():808808. PubMed ID: 35372058
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of primary tumour resection on patients with synchronous metastatic colorectal cancer treated with cetuximab-containing regimens.
    Sertesen E; Yekedüz E; Köksoy EB; Ürün Y; Erkek AB; Demirci S; Ünal AE; Utkan G
    ANZ J Surg; 2023 Apr; 93(4):945-950. PubMed ID: 36259228
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.
    Sartore-Bianchi A; Di Nicolantonio F; Nichelatti M; Molinari F; De Dosso S; Saletti P; Martini M; Cipani T; Marrapese G; Mazzucchelli L; Lamba S; Veronese S; Frattini M; Bardelli A; Siena S
    PLoS One; 2009 Oct; 4(10):e7287. PubMed ID: 19806185
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and Safety of a Parenteral Nutrition Program for Patients with
    Chang YT; Chen CC; Chang SC; Chang YY; Lin BW; Chen HH; Hsieh YY; Hsu HC; Hsieh MC; Kuan FC; Wu CC; Lu WC; Su YL; Liang YH; Chen JB; Huang SY; Huang CW; Wang JY
    Nutrients; 2023 Jun; 15(13):. PubMed ID: 37447297
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.
    Pander J; Gelderblom H; Antonini NF; Tol J; van Krieken JH; van der Straaten T; Punt CJ; Guchelaar HJ
    Eur J Cancer; 2010 Jul; 46(10):1829-34. PubMed ID: 20418097
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
    Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
    BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
    Demurtas L; Puzzoni M; Giampieri R; Ziranu P; Pusceddu V; Mandolesi A; Cremolini C; Masi G; Gelsomino F; Antoniotti C; Loretelli C; Meriggi F; Zaniboni A; Falcone A; Cascinu S; Scartozzi M
    Br J Cancer; 2017 Jul; 117(3):315-321. PubMed ID: 28632725
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival.
    Ciardiello D; Famiglietti V; Napolitano S; Esposito L; Pietrantonio F; Avallone A; Maiello E; Cremolini C; Troiani T; Martinelli E; Ciardiello F; Martini G
    Clin Colorectal Cancer; 2022 Jun; 21(2):141-148. PubMed ID: 35101346
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAF
    García-Alfonso P; Lièvre A; Loupakis F; Tadmouri A; Khan S; Barcena L; Stintzing S
    Crit Rev Oncol Hematol; 2022 May; 173():103646. PubMed ID: 35344913
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumour location and efficacy of first-line EGFR inhibitors in
    Benavides M; Díaz-Rubio E; Carrato A; Abad A; Guillén C; Garcia-Alfonso P; Gil S; Cano MT; Safont MJ; Gravalos C; Manzano JL; Sánchez A; Alcaide J; López R; Massutí B; Sastre J; Martínez E; Escudero P; Méndez M; Aranda E
    ESMO Open; 2019; 4(6):e000599. PubMed ID: 31803504
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of first-line cetuximab in wild-type RAS metastatic colorectal cancer according to tumour BRAF mutation status from the EREBUS cohort.
    Rouyer M; François E; Sa Cunha A; Monnereau A; Bignon E; Jové J; Lassalle R; Droz-Perroteau C; Moore N; Noize P; Fourrier-Réglat A; Smith D
    Br J Clin Pharmacol; 2021 Mar; 87(3):1120-1128. PubMed ID: 32656857
    [TBL] [Abstract][Full Text] [Related]  

  • 54. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
    Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study.
    Köhne CH; Poston G; Folprecht G; Ciardiello F; Ronga P; Beier F; Van Cutsem E
    Eur J Surg Oncol; 2016 Oct; 42(10):1540-7. PubMed ID: 27575968
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of third-line anti-EGFR-based treatment versus regorafenib or trifluridine/tipiracil according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients.
    Salvatore L; Bensi M; Vivolo R; Zurlo IV; Dell'Aquila E; Grande R; Anghelone A; Emiliani A; Citarella F; Calegari MA; Ribelli M; Basso M; Pozzo C; Tortora G
    Front Oncol; 2023; 13():1125013. PubMed ID: 36895480
    [TBL] [Abstract][Full Text] [Related]  

  • 57. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
    Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
    Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab.
    Martini G; Ciardiello D; Dallio M; Famiglietti V; Esposito L; Corte CMD; Napolitano S; Fasano M; Gravina AG; Romano M; Loguercio C; Federico A; Maiello E; Tuccillo C; Morgillo F; Troiani T; Di Maio M; Martinelli E; Ciardiello F
    Int J Cancer; 2022 Aug; 151(3):473-480. PubMed ID: 35429341
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease.
    Bruera G; Cannita K; Di Giacomo D; Lamy A; Troncone G; Dal Mas A; Coletti G; Frébourg T; Sabourin JC; Tosi M; Ficorella C; Ricevuto E
    BMC Med; 2012 Nov; 10():135. PubMed ID: 23136868
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: a single center study.
    Ulivi P; Capelli L; Valgiusti M; Zoli W; Scarpi E; Chiadini E; Rosetti P; Bravaccini S; Calistri D; Saragoni L; Casadei Gardini A; Ragazzini A; Frassineti GL; Amadori D; Passardi A
    J Transl Med; 2012 May; 10():87. PubMed ID: 22569004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.